FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis.

about

FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis.

Item

http://www.wikidata.org/entity/Q54994574

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis.

@en

FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis.

@nl

type

Item

label

FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis.

@en

FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis.

@nl

prefLabel

FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis.

@en

FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis.

@nl

P1476

FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis.

@en

P2093

Hong Bu

http://www.w3.org/2001/XMLSchema#string

Peng Guo

http://www.w3.org/2001/XMLSchema#string

Shinan Chen

http://www.w3.org/2001/XMLSchema#string

Tianjie Pu

http://www.w3.org/2001/XMLSchema#string

Yan Qiu

http://www.w3.org/2001/XMLSchema#string

Ye Feng

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive molecular portraits of human breast tumours

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Untangling the ErbB signalling network

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer.

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.

Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications

P304

8206-8214

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2018.8423

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29805554

http://www.w3.org/2001/XMLSchema#string

P932

5950032

http://www.w3.org/2001/XMLSchema#string